Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ. Pollock Y, et al. Among authors: londhe a. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):813. doi: 10.1038/s41391-023-00683-1. Prostate Cancer Prostatic Dis. 2023. PMID: 37620428 No abstract available.
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P. Mateos MV, et al. Among authors: londhe a. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):385-393. doi: 10.1016/j.clml.2023.02.006. Epub 2023 Mar 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36967244 Clinical Trial.
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee. Papp KA, et al. Among authors: londhe a. J Drugs Dermatol. 2012 Oct;11(10):1210-7. J Drugs Dermatol. 2012. PMID: 23134986
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Saad F, et al. Among authors: londhe a. Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16. Eur Urol. 2015. PMID: 25985882 Free PMC article.
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE, Ryan CJ, Scher HI, Shore ND, De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, Montgomery B. Fizazi K, et al. Among authors: londhe a. Eur Urol. 2016 Sep;70(3):438-44. doi: 10.1016/j.eururo.2016.02.035. Epub 2016 Mar 7. Eur Urol. 2016. PMID: 26965562 Free PMC article.
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW. Ryan CJ, et al. Among authors: londhe a. J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6. J Urol. 2018. PMID: 29630978 Free PMC article. Clinical Trial.
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. Kipps TJ, et al. Among authors: londhe a. Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6. doi: 10.1016/j.clml.2019.07.004. Epub 2019 Jul 15. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31447270 Free article.
75 results